WEED.TO - Canopy Growth Corporation

Toronto - Toronto Delayed Price. Currency in CAD
46.61
-1.08 (-2.26%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close47.69
Open47.50
Bid46.69 x 0
Ask46.69 x 0
Day's Range46.41 - 47.68
52 Week Range31.81 - 76.68
Volume1,144,963
Avg. Volume2,041,382
Market Cap16.121B
Beta (3Y Monthly)5.15
PE Ratio (TTM)N/A
EPS (TTM)-2.57
Earnings DateAug 14, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est71.08
  • 'Aurora is burning cash': Bank of America downgrades cannabis producer
    Yahoo Finance Canada10 hours ago

    'Aurora is burning cash': Bank of America downgrades cannabis producer

    Aurora Cannabis Inc. has been downgraded by Bank of America Merrill Lynch, citing concern over the company’s cash burn and pending debt payments.

  • Aurora Cannabis Stock Falls on Bank of America Downgrade
    Market Realist7 hours ago

    Aurora Cannabis Stock Falls on Bank of America Downgrade

    On Thursday, Bank of America downgraded Aurora Cannabis stock (ACB) to “neutral” from its previous “buy” rating. Here's why.

  • Ranking the Top 3 Cannabis Companies Today
    The Motley Fool13 hours ago

    Ranking the Top 3 Cannabis Companies Today

    If I were to rate the Top 3 cannabis companies today, Aurora Cannabis Inc. (TSX:ACB)(NYSE:ACB) would rank no.1 and Aphria Inc. (TSX:APHA)(NYSE:APHA) in third. Canopy Growth Corp. (TSX:WEED)(NYSE:CGC) has fallen to second best.

  • Should You Buy Shares of This Top Cannabis Stock After Earnings?
    The Motley Fool14 hours ago

    Should You Buy Shares of This Top Cannabis Stock After Earnings?

    Here is how OrganiGram Holdings Inc (TSXV:OGI) (NASDAQ:OGI) performed during the last quarter.

  • 3 Cannabis Stocks Worth Considering for Your Portfolio
    Motley Fool14 hours ago

    3 Cannabis Stocks Worth Considering for Your Portfolio

    MediPharm Labs, Canopy Growth, and OrganiGram get some love from three of our contributors who cover the marijuana space.

  • Why Is the US CBD Market So Attractive?
    Market Realist15 hours ago

    Why Is the US CBD Market So Attractive?

    Brightfield Group estimates that the CBD market could hit about $23.7 billion by 2023. However, regulatory hurdles could impact the US market.

  • Buy This 1 Weed Stock Instead of Canopy Growth (TSX:WEED)
    The Motley Fool21 hours ago

    Buy This 1 Weed Stock Instead of Canopy Growth (TSX:WEED)

    With the slump in Canopy Growth Corp. (TSX:WEED)(NYSE:CGC)'s stock price, it might be time to consider this stock instead.

  • Motley Fool2 days ago

    Canopy Growth Just Confirmed What We've Long Suspected

    Canopy CFO Mike Lee dishes on growth expectations for fiscal 2020.

  • This Colombian Girl-Boss Leads Medical Cannabis
    The Motley Fool3 days ago

    This Colombian Girl-Boss Leads Medical Cannabis

    Learn about the woman behind Spectrum Cannabis and Canopy Growth Corp's (TSX:WEED)(NYSE:CGC) bold acquisition.

  • How the New NAFTA Affects Cannabis Stocks
    The Motley Fool3 days ago

    How the New NAFTA Affects Cannabis Stocks

    What investors need to know about CUSMA and Canopy Growth Corp (TSX:WEED)(NYSE:CGC).

  • What Is the Legal Global Marijuana Market Really Worth?
    The Motley Fool3 days ago

    What Is the Legal Global Marijuana Market Really Worth?

    Canopy Growth Corp. (TSX:WEED)(NYSE:CGC) is the best positioned cultivator to take advantage of the growing legal marijuana market.

  • A $10,000 Investment in Weed Stocks at the Beginning of 2019 Is Worth This Much Today
    The Motley Fool3 days ago

    A $10,000 Investment in Weed Stocks at the Beginning of 2019 Is Worth This Much Today

    If you'd invested $10,000 in Aurora Cannabis Inc (TSX:ACB)(NYSE:ACB) at the beginning of the year, you'd have this much today.

  • Cannabis Outlook From OrganiGram’s Earnings Report
    Market Realist3 days ago

    Cannabis Outlook From OrganiGram’s Earnings Report

    On Monday, OrganiGram (OGI) reported its third-quarter earnings. Following the company's earnings, we reported how it performed in the third quarter. To learn more, read OrganiGram’s Third-Quarter Earnings. Interestingly, OrganiGram stressed that the growth would be heavily driven by retail stores opening in Ontario and Quebec. The company stated that legalizing edibles and derivative products […]

  • 7 Reasons Aurora, Canopy, Cronos, and HEXO Are All At or Near 6-Month Lows
    Motley Fool3 days ago

    7 Reasons Aurora, Canopy, Cronos, and HEXO Are All At or Near 6-Month Lows

    The buzz is beginning to wear off for the most popular cannabis stocks.

  • Organigram a Canadian Pot Rarity After Four Profitable Quarters
    Bloomberg3 days ago

    Organigram a Canadian Pot Rarity After Four Profitable Quarters

    (Bloomberg) -- With four quarters of profitability under its belt, Organigram Holdings Inc. is an anomaly in the Canadian cannabis market.Organigram has higher margins than most of its peers and one of the lowest costs per gram in the industry even though it grows indoors, generally considered the most expensive method of production. Chief Executive Officer Greg Engel attributes this to its ability to get higher yields from its pot plants than companies that grow in greenhouses, as well as its automated packaging lines.“We built a facility and designed a facility that was very focused on high-quality product because we felt there was a market opportunity that was sustainable,” Engel said in an interview at Bloomberg’s Toronto office.Organigram’s streak of profitability comes as the industry undergoes a period of significant upheaval. CannTrust Holdings Inc., previously considered one of the more reputable pot companies, plunged 48% last week after Canadian regulators said it grew cannabis in unlicensed areas of its greenhouse, forcing it to halt all sales and shipments of its products.That came less than a week after Canopy Growth Corp. fired co-CEO Bruce Linton amid shrinking margins and a C$323 million net loss in its most recent quarter.Lower ValuationMoncton, New Brunswick-based Organigram, meanwhile, reported its fourth consecutive quarter on Monday of positive adjusted earnings before interest, taxes, depreciation and amortization, or Ebitda. Revenue of C$25 million ($19 million) missed estimates and gross margin fell to 50% from 60% in the previous quarter, but Eight Capital analyst Graeme Kreindler said he views this as an “isolated event” related to a temporary change in cultivation protocols and the timing of shipments to provinces.Organigram said it cost 95 cents to produce a gram of dried flower in its most recent quarter. That was up from 65 cents in the previous quarter but still compares favorably with C$1.42 at Aurora Cannabis Inc. and $1.48 at Tilray Inc.No other large Canadian pot producer has managed to post such a long string of positive Ebitda. However, although it’s one of the best-performing pure-play pot stocks this year, up 64%, its valuation as measured by its price-to-sales ratio is well below those of its largest competitors.Engel is unperturbed. “At the end of the day, the worst thing that can happen to a company is you’ve got an artificial stock price that you can’t sustain,” Engel said.Competitors also spend a lot on stock promotion, he said. This “may in the short term be helping their stock price, but I’m not sure that’s sustainable without ongoing spending,” he said.The problems at CannTrust and Canopy signal a shakeout in an industry that’s still maturing nine months after Canada legalized recreational pot. Organigram is lucky because it had its wake-up call early, said Engel.The company had to recall several lots of its medical pot in late 2016 and early 2017 after it was found to contain an unapproved pesticide. Engel, who was CEO of Tilray Inc. at the time, was hired after the recall to “make a major cultural shift,” he said.“As a result of that recall, we had monthly ongoing inspections by regulators, and historically the industry was always complaining or defensive about the inspections,” Engel said. “My approach was to embrace them. At the end of the day it’s a partnership, not an adversarial relationship.”In the interview, Engel shared his views of the nascent industry:Beverages and EdiblesOrganigram isn’t being coy about its desire for a partner that can help it develop cannabis-infused beverages, similar to Constellation Brands Inc.’s investment in Canopy, Tilray’s partnership with Anheuser-Busch InBev SA or Hexo Corp.’s joint venture with Molson Coors Brewing Co.Organigram has developed a rapid-onset technology that will allow its drinks to take effect within 10 to 15 minutes, similar to alcohol, and has also created a flavorless cannabis powder that can be added to any beverage.“We wanted to go to these negotiations offering as much as possible,” Engel said. Organigram is seeking a partner from the alcohol industry that can help it develop beverages infused with THC, the cannabis compound that gets you high. It’s also seeking a consumer packaged goods partner for drinks infused with CBD, a non-intoxicating substance that’s thought to have health and wellness properties.BiosyntheticsEngel hopes Organigram’s investment in Montreal-based Hyasynth Biologicals Inc. will also help it lure a partner. Hyasynth is developing large-scale biosynthetic production of cannabinoids, or the active compounds found in cannabis. This method, which uses yeast to produce the compounds in a lab, is cheaper than extracting them from plants and will help lower production costs for products like beverages, edibles and vape pens, said Engel.U.S. Market“We’re very actively looking at the CBD market in the U.S.,” where the substance is legal at the federal level as long as it’s derived from hemp with very low THC content, Engel said. Organigram doesn’t plan to grow its own hemp but is looking at a range of possibilities, including investments in existing brands, products and companies.Corporate GovernanceOrganigram has a fully independent board of directors, a rarity in the cannabis sector. The CEO sees good corporate governance as essential to a well-run pot company.“This is an industry that’s still very much moving from founders and executives being chairmen or multiple insiders on boards, and I think some of the challenges we’ve seen in the industry have been because of a lack of governance,” he said. “You have to have independent governance that has oversight and holds management accountable.”To contact the reporter on this story: Kristine Owram in Toronto at kowram@bloomberg.netTo contact the editors responsible for this story: Brad Olesen at bolesen3@bloomberg.net, ;David Scanlan at dscanlan@bloomberg.net, Jacqueline ThorpeFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • OrganiGram’s Third-Quarter Earnings
    Market Realist4 days ago

    OrganiGram’s Third-Quarter Earnings

    On Monday morning, OrganiGram's third-quarter earnings came in as a bit of a let-down. Here's why.

  • 1 Top Cannabis Stock You Can Buy and Hold for the Next Decade
    Motley Fool4 days ago

    1 Top Cannabis Stock You Can Buy and Hold for the Next Decade

    This company can help you cash in on the global marijuana boom.

  • These 2 “What ifs” Could Kill Your Cannabis Stocks
    The Motley Fool4 days ago

    These 2 “What ifs” Could Kill Your Cannabis Stocks

    Canopy Growth Corp (TSX:WEED)(NYSE:CGC) and the cannabis sector in general could be heavily impacted by two plausible scenarios.

  • Organigram will be ‘doing more with less’ as investors demand frugal spending
    Yahoo Finance Canada4 days ago

    Organigram will be ‘doing more with less’ as investors demand frugal spending

    Organigram Holdings Inc. (OGI)(OGI.V) reported a $10.2 million net loss in its fiscal third quarter, or negative $0.07 per share.

  • 3 Oversold Stocks That Could Be Great Buys Right Now
    The Motley Fool4 days ago

    3 Oversold Stocks That Could Be Great Buys Right Now

    BlackBerry Ltd (TSX:BB)(NYSE:BB) and these two other stocks look to be attractive buys on the dip as they've seen some excessively bearish activity as of late.

  • Pricey Weed Stocks: A Lesson From Cheap Oil
    The Motley Fool4 days ago

    Pricey Weed Stocks: A Lesson From Cheap Oil

    The wild prices and IPOs of the oil bubble should have made investors sceptical of stocks such as Canopy Growth (NYSE:CGC)(TSX:WEED), yet they continue to overlook familiar trends.

  • Which Marijuana Stock Is the Best to Hold in This Bearish Spell?
    The Motley Fool5 days ago

    Which Marijuana Stock Is the Best to Hold in This Bearish Spell?

    Canopy Growth Corp (TSX:WEED)(NYSE:CGC) is still the best marijuana stock to buy, even in this environment of uncertainty.

  • Canopy Growth (TSX:WEED) Dumped its Visionary: Investors Should Do the Same to the Stock!
    The Motley Fool5 days ago

    Canopy Growth (TSX:WEED) Dumped its Visionary: Investors Should Do the Same to the Stock!

    Canopy Growth Corp (TSX:WEED)(NYSE:CGC) stock has been struggling in recent months, and things might not be getting better anytime soon.

  • Better Marijuana Stock: Canopy Growth vs. Constellation Brands
    Motley Fool5 days ago

    Better Marijuana Stock: Canopy Growth vs. Constellation Brands

    Pure-play pot stock or its big partner? Here's which stock looks more attractive over the long run.

  • Canopy Growth (TSX:WEED): Beware the Disruptive Cronos Group (TSX:CRON)
    The Motley Fool6 days ago

    Canopy Growth (TSX:WEED): Beware the Disruptive Cronos Group (TSX:CRON)

    Cronos Group Inc. (TSX:CRON)(NASDAQ:CRON) seems very keen on disrupting the cannabis industry before Canopy Growth (TSX:WEED)(NYSE:CGC) enjoys leadership benefits.